Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Redcliffe Labs Announces Leadership Transition to Drive Healthcare Accessibility

Home
/
update
/
details

ICMR Collaborates with Industry and Academia to Initiate First-in-Human Phase 1 Clinical Trials

NextEdge Admin

14 Sep 2024

2 min 18 sec

In a major move to bolster India's clinical research landscape, the Indian Council of Medical Research (ICMR) has signed Memorandum of Agreements (MoAs) with multiple sponsors as part of its Network for phase 1 clinical trials. This marks India’s entry into first-in-human clinical trials for four innovative molecules.

The partnerships include research on a small molecule for multiple myeloma with Aurigene Oncology Limited, Zika vaccine development with Indian Immunologicals Limited, a seasonal influenza vaccine trial with Mynvax Private Limited, and a CAR-T cell therapy study for chronic lymphocytic leukemia with ImmunoACT.

This initiative positions India as a leader in the clinical development of pharmaceutical agents, according to the Union Health Ministry. Union Health Minister J.P. Nadda hailed the collaboration as a significant milestone towards making cutting-edge treatments affordable and accessible to all.

Dr. Rajiv Bahl, Secretary of the Department of Health Research and Director General of ICMR, emphasized the importance of strategic public-private partnerships in advancing clinical research. He noted that the phase 1 clinical trial network aims to develop indigenous molecules and innovative treatments, reflecting ICMR’s commitment to affordable healthcare.

The network includes four premier institutions across India—KEMH & GSMC in Mumbai, ACTREC in Navi Mumbai, SRM MCH&RC in Kattankulathur, and PGIMER in Chandigarh—backed by a Central Coordinating Unit at ICMR headquarters in New Delhi. These agreements strengthen ICMR's partnerships with industry and academia, furthering India’s leadership in clinical research.